References
- Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection 1990; 18 (Suppl. 2): S75-S76.
- Ferrari V, Bonanomi L, Borgia M, Lodola E, Marca GA. A new fosfomycin derivative with much improved bioavailability by oral route. Chemioterapia 1981; 4: 59–63.
- Sabada B, Lopez de Ocariz A, Dios C, Fos D, Azanza JR, Honorato J. Concentraciones urinarias de fosfomicina tras la administración de una dosis Unica de fosfomicina trometa-mol: Aplicación a la terapia monodosis de las infecciones uri-narias. Rev Esp Quimioterap 1995; 8: 229–32.
- Pavesio D, Pecco P, Bianchi E, Segre G. Pharmacokinetics in children of a new fosfomycin derivative with improved bioavailability. In: Recents Advances in Chemotherapy. Proceedings of the 14th International Congress of Chemotherapy ( Kyoto, 1985). Antimicrobial Section 3. Tokyo: Tokyo University Press, 1986; 1911-1912.
- Segre G, Bianchi E, Cataldi A, Zannini G. Pharmacokinetic profile of fosfomycin trometamol. Eur Urol 1987; 13 (Suppl. 1): 56-63.
- Wilson P, Williams JD, Ronaldi E. Comparative phar-macokinetics of fosfomycin trometamol, sodium fosfomycin and calcium fosfomycin in humans. In: New Trends in Urinary Tract Infections, Neu HC, Williams JD ( Eds.), Basel: Karger, 1988: 136-42.
- Boerema JBJ. Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncom-plicated urinary infections in general practice. Infection 1990; 18 (Suppl. 2): S80-S88.
- Corbusier A, Germeau F, Bonadio M. Fosfomycin trometamol versus amoxycillin single-dose therapy. In: New Trends in Urinary Tract Infections, Neu HC, Williams JD ( Eds.), Basel: Karger, 1988: 185-90.
- National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobicaly, 2nd Ed. Approved Standard. M7-A2. NCCLS, Villanova, Pa. 1990.
- Andrews JM, Baquero F, Beltran JM, CantOn E, Crokaert F, Gobemado M. International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother 1983; 12: 357–61.
- Barry AL, Fuchs PC. In vitro susceptibility testing pro-cedures for fosfomycin tromethamine. Antimicrob Agents Chemother 1991; 35: 1235–8.
- National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing. M100-54. NCCLS, Villanova, Pa. 1992.
- Forsgren A, Walder M. Antimicrobial activity of fos-fomycin in vitro. J Antimicrob Chemother 1983; 11: 467–71.
- Greeenwood D, Coyle A, Andrew J. The trometamol salt of fosfomycin: microbiological evaluation. Eur Urol 1987; 13 (Suppl. 1): 69-75.
- King A, Phillips I. Comparative in vitro activity of fos-fomycin trometamol against urinary tract pathogens. In: New Trends in Urinary Tract Infections, Neu HC, Williams JD ( Eds.), Basel: Karger, 1988: 242-9.
- Wise R, Andrews JM. Fosfomycin trometamol: an in vitro study. In: New Trends in Urinary Tract Infections, Neu HC, Williams JD ( Eds.), Basel: Karger, 1988: 232-41.